The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.50%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 40.50
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Changes

17 May 2022 07:00

RNS Number : 6837L
Venture Life Group PLC
17 May 2022
 

17th May 2022

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Directorate Changes

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces the appointment of Mr Paul McGreevy as Non-executive Chair of the Company with immediate effect and consequent stepping down from the Board of Dr. Lynn Drummond.

Mr McGreevy is an experienced and successful executive with over 30 years commercial experience in the consumer healthcare and products industry. He has a strong track record of demonstrating commercial success in Omni-channel sales across FMCG and is experienced in franchise, wholesale and manufacturing, as well as having established credentials in internationalising consumer products and businesses.

Mr McGreevy spent his early career with Walgreen Boots Alliance in the UK in R&D, sales, and marketing between 1993 & 1999. This was followed by a period at Dewhirst Group as R&D and Commercial Director. He joined The Body Shop International in 2004 as Global Product Director, then moving on to become Global Operations Director, having additional responsibilities of R&D, acquisitions and divestments. During his 10 years at The Body Shop, he had responsibilities to over 70 markets and oversaw significant growth and expansion of the business.

Since leaving The Body Shop, Mr McGreevy has pursued a successful Non-executive career, as both Chair and Non-executive Director of several international consumer product businesses. He has current board appointments in consumer businesses with a focus on brand, product development, operations, and R&D, with Danish retail chain, Normal A/S, and cosmetics manufacturing company, SnJ International Limited, whilst also also running his own consultancy business, McGreevy Consulting Ltd.

 

Jerry Randall, CEO of Venture Life commented: "We are delighted to have Paul join the Board of Venture Life Group as our new Non-executive Chair. His extensive experience in the international consumer healthcare market will be invaluable to us. In particular, Paul's knowledge of the omni-channel approach to sales and marketing is very pertinent to us as we seek to grow our brands and our business through the many channels available to us in today's market. As an experienced board Director and Chair, Paul brings additional and considerable governance experience to our Board, and we look forward to working with him.

On behalf of the whole Board, I also extend our deepest thanks and gratitude to our outgoing Chair, Dr Lynn Drummond. Lynn has been with us since before our IPO in 2014 and has helped us navigate the difficult path of becoming a growing and sustainably profitable consumer healthcare business on the public markets. We thank Lynn for her time with us and wish her all the very best for the future.

Paul McGreevy commented: "I am very excited to join such an ambitious team, with a great portfolio of brands that provides a solid foundation to accelerate our growth in the self-care sector. VLG is well placed in a growing market to further develop its brands, expand through acquisition, and increase its international footprint." 

 

Further information on Paul McGreevy

Paul Brian McGreevy (aged 54) has held the following directorships in the past 5 years:

Current Directorships:

· McGreevy Consulting Ltd

· S&J International (UK) Limited

· Normal A/S

Previous Directorships held in the past 5 years:

· Age UK Lancashire

· Kennelpak Group Ltd

· Kennelpak Holdings Ltd

There is no further information on Paul McGreevy required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cenkos Securities plc (Nomad and Joint Broker)

 

+44 (0) 20 7397 8900

Michael Johnson/Russell Kerr (Sales)

Stephen Keys/Camilla Hume (Corporate Finance)

 

 

Singer Capital Markets (Joint Broker)

 

+44 (0) 20 7496 3000

Jonathan Dighe (Sales)

Shaun Dobson/Alaina Wong (Corporate Finance)

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKZGMKVVNGZZM
Date   Source Headline
7th Oct 201910:57 amRNSHolding(s) in Company
20th Sep 20197:00 amRNSHalf-year Report - Amendment
19th Sep 20197:00 amRNSInterim Results
17th Jul 20197:00 amRNSCommercial update
11th Jul 20193:33 pmRNSDirector/PDMR Shareholding
8th Jul 20195:02 pmRNSHolding(s) in Company
25th Jun 20198:44 amRNSDirector/PDMR Shareholding
3rd Jun 201911:36 amRNSResult of AGM
17th May 20194:35 pmRNSPrice Monitoring Extension
1st May 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSFinal Results
26th Mar 20195:17 pmRNSHolding(s) in Company
20th Mar 20197:00 amRNSNotice of Results Update
29th Jan 20197:00 amRNSTrading and Commercial Update
5th Dec 20183:26 pmRNSHolding(s) in Company
5th Dec 20188:12 amRNSHolding(s) in Company
23rd Nov 20187:00 amRNSChange of adviser and directorate update
15th Nov 20187:00 amRNSCommercial update
20th Sep 20187:01 amRNSDirectorate Change
20th Sep 20187:00 amRNSHalf-year Report
16th Aug 20187:00 amRNSTrading update & notice of interim results
13th Aug 201812:17 pmRNSHolding(s) in Company
8th Aug 20182:15 pmRNSHolding(s) in Company
8th Aug 20187:00 amRNSCompletion of Placing and Acquisition
7th Aug 20184:54 pmRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201810:10 amRNSHolding(s) in Company
6th Aug 201811:51 amRNSResult of General Meeting
23rd Jul 20184:00 pmRNSHolding(s) in Company
20th Jul 20187:00 amRNSPlacing, proposed acquisition and notice of GM
20th Jul 20187:00 amRNSAppointment of Joint Broker
19th Jul 20183:38 pmRNSHolding(s) in Company
18th Jun 20187:00 amRNSIncreased distribution of UltraDEX in Boots, UK
4th Jun 20187:00 amRNSLloyds Pharmacy to list UltraDEX in UK
23rd May 201812:29 pmRNSResult of AGM
21st May 20187:00 amRNS'1000 Companies to Inspire Britain' 2018 report
9th May 20187:00 amRNSAlliance Pharma contract expansion and extension
8th May 20182:54 pmRNSHolding(s) in Company
30th Apr 20187:00 amRNSUltraDEX update
17th Apr 20187:00 amRNSDirector/PDMR Shareholding
5th Apr 20187:00 amRNSDirector/PDMR Shareholding
27th Mar 20187:00 amRNSDirector/PDMR Shareholding
26th Mar 20187:00 amRNS2018 LTIP and Grant of Options to PDMRs
22nd Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of analyst & investor results briefings
16th Feb 20187:00 amRNSInvestor presentation
13th Feb 20187:00 amRNSCommerical update
31st Jan 20187:00 amRNSTrading update
8th Jan 20187:00 amRNSEuropean Business Awards 'Ones to Watch List'

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.